Oculis Holding AG Ordinary Shares OCS 深 滬
等待開盤 12-12 09:30:00 美东时间
20.88
+0.250
+1.21%
華盛通- 最 高21.00
- 今 開20.63
- 成交量 4.89万股
- 最 低 20.45
- 昨 收 20.63
- 總市值 10.66亿
- 52周最高 23.08
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 14.00
- 委 比 65.64%
- 總股本 5103.37万
- 歷史最高 23.08
- 量 比 0.44
- 振 幅 2.67%
- 歷史最低 6.26
- 每 手 1
- 風險率 1.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
LifeSci Capital Initiates Coverage On Oculis Holding with Outperform Rating, Announces Price Target of $55
LifeSci Capital initiates coverage on Oculis Holding (NASDAQ:OCS) with a Outperform rating and announces Price Target of $55.
12-03 21:55
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Needham Reiterates Buy on Oculis Holding, Maintains $36 Price Target
Needham analyst Serge Belanger reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $36 price target.
11-11 19:04
Oculis Holding Q3 EPS $(0.32) Beats $(0.50) Estimate, Sales $243.000K Miss $250.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.50) by 36 percent. This is a 41.82 percent increase over losses of $(0.55) per share from the
11-11 05:45
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Oculis Raises $110M Through Oversubscribed Offering To Advance Privosegtor Clinical Development And Strengthen Ophthalmology Pipeline
Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior
10-30 16:33
喜报！参投公司孛璞半导体中标硅光领域前沿项目
在人工智能浪潮席卷全球的今天，算力已然成为驱动产业智能化的核心引擎。 近日，上海孛璞半导体技术有限公司（以下简称“孛璞半导体”）成功中标上海市科委战略前沿专项项...
10-30 09:40
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
Oculis Holding AG announced the pricing of an aggregate of 5,432,298 ordinary shares at $20.25 per share, raising $110 million in gross proceeds. The company plans to use the funds to advance its Privosegtor candidate for treating acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, as well as for general corporate purposes. The offering includes 4,691,358 shares in an underwritten offering and 740,740 shares in a registered...
10-30 08:17
